Comparative proteomic analysis of human osteosarcoma and SV40-immortalized normal osteoblastic cell lines

Acta Pharmacologica Sinica

Volumn 28, Issue 6, 2007, Pages 850-858

  Guo, Qian Chen ^a   Shen, Jing Nan ^a   Jin, Song ^a   Wang, Jin ^a   Huang, Gang ^a   Zhang, Long Juan ^a   Yin, Jun Qiang ^a   Zou, Chang Ye ^a   Li, Ming Tao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

AHA1; Differentially produced protein; Osteosarcoma; Proteome; SLP 2

Indexed keywords

ACTIVATOR OF KDA SHOCK PROTEIN ATPASE HOMOLOG 1; PROTEIN; STOMATIN LIKE PROTEIN 2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CELL CULTURE; CELL IMMORTALIZATION; CONTROLLED STUDY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OSTEOBLAST; OSTEOSARCOMA CELL; PROTEOMICS; SIMIAN VIRUS 40; WESTERN BLOTTING;

CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MOLECULAR SEQUENCE DATA; OSTEOBLASTS; OSTEOSARCOMA; PEPTIDE MAPPING; PROTEOME; PROTEOMICS; SIMIAN VIRUS 40; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 34249278146     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00603.x     Document Type: Article

References (33)

1. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet, 2003 145 : 1 30.
2. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist, 2004 9 : 422 41.
3. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocals. J Clin Oncol, 2002 20 : 776 90.
4. Zeindl-Eberhar E, Haraida S, Liebmann S, Jungblut PR, Mayer D, Jager G, et al. Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology, 2004 39 : 540 49.
5. Li C, Chen Z, Xiao Z, Wu X, Zhan X, Zhang X, et al. Comparative proteomics analysis of human lung squamous carcinoma. Biochem Biophys Res Commun, 2003 309 : 253 60.
6. Johansson B, Pourian MR, Chuan YC, Byman I, Bergh A, Pang ST, et al. Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heat shock protein 60 as a marker for prostate malignancy. Prostate, 2006 66 : 1235 44.
7. An HJ, Kim DS, Park YK, Kim SK, Choi YP, Kang K, et al. Comparative proteomics of ovarian epithelial tumors. J Proteome Res, 2006 5 : 1082 90.
8. Afjehi-Sadat L, Shin JH, Felizardo M, Lee K, Slavc I, Lubec G. Detection of hypothetical proteins in 10 individual human tumor cell lines. Biochim Biophys Acta, 2005 1747 : 67 80.
9. Wolf M, El-Rifai W, Tarkkanen M, Kononen J, Serra M, Eriksen EF, et al. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet Cytogenet, 2000 123 : 128 32.
10. Atiye J, Wolf M, Kaur S, Monni O, Bohling T, Kivioja A, et al. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer, 2005 42 : 158 63.
11. Spreafico A, Frediani B, Capperucci C, Chellini F, Paffetti A, D'Ambrosio C, et al. A proteomic study on human osteoblastic cells proliferation and differentiation. Proteomics, 2006 6 : 3520 32.
12. Zhang L, Ding F, Cao W, Liu Z, Yu Z, Wu Y, et al. Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma. Clin Cancer Res, 2006 12 : 1639 46.
13. Lynch M, Chen L, Ravitz MJ, Mehtani S, Korenblat K, Pazin MJ, et al. HnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation. Mol Cell Biol, 2005 25 : 6436 53.
14. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol, 2005 15 : 300 8.
15. Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, et al. AT P binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 1998 17 : 4829 36.
16. Obermann WM, Sondermann H, Russo AA, Pavletich N P, Hartl FU. In vivo function of Hsp90 is dependent on ATP binding and AT P hydrolysis. J Cell Biol, 1998 16 : 901 10.
17. Lotz GP, Lin H, Harst A, Obermann WM. Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J Biol Chem, 2003 278 : 17 228 35.
18. Mayer MP, Nikolay R, Bukau B. Aha, another regulator for Hsp90 chaperones. Mol Cell, 2002 10 : 1255 6.
19. Stiligardi G, Panaretou B, Meyer P, Singh S, Woolfson DN, Pearl LH, et al. Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J Biol Chem, 2002 277 : 20 151 9.
20. Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S, et al. Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone Aha1. Mol Cell, 2002 10 : 1307 18.
21. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 2003 425 : 407 10.
22. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med, 2002 8 : S55 61.
23. Wang Y, Morrow JS. Identification and characterization of human SLP-2, a novel homologue of stomatin (band 7.2b) present in erythrocytes and other tissues. J Biol Chem, 2000 275 : 8062 71.
24. John J P, Anrather D, Pollak A, Lubec G. Mass spectrometrical verification of stomatin-like protein 2 (SLP-2) primary structure. Proteins, 2006 64 : 543 51.
25. Owczarek CM, Treutlein HR, Portbury KJ, Gulluyan LM, Kola I, Hertzog PJ. A novel member of the STOMATIN/EPB72/mec-2 family, stomatin-like 2 (STOML2), is ubiquitously expressed and localizes to HSA chromosome 9p13.1. Cytogenet Cell Genet, 2001 92 : 196 203.
26. Hasina R, Hulett K, Bicciato S, Di Bello C, Petruzzelli GJ, Lingen MW. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res, 2003 63 : 555 9.
27. Whitbread AK, Masoumi A, Tetlow N, Schmuck E, Coggan M, Board PG. Characterization of the omega class of glutathione transferases. Methods Enzymol, 2005 401 : 78 99.
28. Dulhunty A, Gage P, Curtis S, Chelvanayagam G, Board P. The glutathione transferase structural family includes a nuclear chloride channel and a ryanodine receptor calcium release channel modulator. J Biol Chem, 2001 276 : 3319 23.
29. Marahatta SB, Punyarit P, Bhudisawasdi V, Paupairoj A, Wongkham S, Petmitr S. Polymorphism of glutathione S-trans-ferase omega gene and risk of cancer. Cancer Lett, 2006 236 : 276 81.
30. Peene I, Meheus L, Keyser SD, De-Keyser S, Humbel R, Veys EM, et al. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis, 2002 61 : 929 33.
31. Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, et al. Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci, 2006 97 : 380 6.
32. Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, Haller O. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis, 1994 169 : 807 13.
33. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res, 2005 11 : 8006 14.